Variable evidence on metformin efficiency as weight-reducing and antiblastomogenic agent: causes and consequences
The growing interest to metformin in areas beyond the limits of diabetology serves as a stimulus for further evaluation of its effectiveness as a potential modulator of cancer morbidity and obesity epidemic. Gradually detectable differences in the intensity of these effects of the drug can be explai...
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
Endocrinology Research Centre
2012-06-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://endojournals.ru/index.php/omet/article/view/6540 |
| id |
doaj-fc0be3e415ea40338aafd0a639545cc3 |
|---|---|
| record_format |
Article |
| spelling |
doaj-fc0be3e415ea40338aafd0a639545cc32021-10-02T16:10:11ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242012-06-0192111610.14341/omet2012211-166400Variable evidence on metformin efficiency as weight-reducing and antiblastomogenic agent: causes and consequencesThe growing interest to metformin in areas beyond the limits of diabetology serves as a stimulus for further evaluation of its effectiveness as a potential modulator of cancer morbidity and obesity epidemic. Gradually detectable differences in the intensity of these effects of the drug can be explained by an insufficient number of randomized trials, differences in the control groups (reference points), gender, age, pharmacogenetic and other factors, the study of which collectively promised to increase the likelihood of more favorable clinical effects of metformin and other antidiabetic biguanides in discussed areas.https://endojournals.ru/index.php/omet/article/view/6540metforminobesitycancer morbiditymodifying factors |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| title |
Variable evidence on metformin efficiency as weight-reducing and antiblastomogenic agent: causes and consequences |
| spellingShingle |
Variable evidence on metformin efficiency as weight-reducing and antiblastomogenic agent: causes and consequences Ожирение и метаболизм metformin obesity cancer morbidity modifying factors |
| title_short |
Variable evidence on metformin efficiency as weight-reducing and antiblastomogenic agent: causes and consequences |
| title_full |
Variable evidence on metformin efficiency as weight-reducing and antiblastomogenic agent: causes and consequences |
| title_fullStr |
Variable evidence on metformin efficiency as weight-reducing and antiblastomogenic agent: causes and consequences |
| title_full_unstemmed |
Variable evidence on metformin efficiency as weight-reducing and antiblastomogenic agent: causes and consequences |
| title_sort |
variable evidence on metformin efficiency as weight-reducing and antiblastomogenic agent: causes and consequences |
| publisher |
Endocrinology Research Centre |
| series |
Ожирение и метаболизм |
| issn |
2071-8713 2306-5524 |
| publishDate |
2012-06-01 |
| description |
The growing interest to metformin in areas beyond the limits of diabetology serves as a stimulus for further evaluation of its effectiveness as a potential modulator of cancer morbidity and obesity epidemic. Gradually detectable differences in the intensity of these effects of the drug can be explained by an insufficient number of randomized trials, differences in the control groups (reference points), gender, age, pharmacogenetic and other factors, the study of which collectively promised to increase the likelihood of more favorable clinical effects of metformin and other antidiabetic biguanides in discussed areas. |
| topic |
metformin obesity cancer morbidity modifying factors |
| url |
https://endojournals.ru/index.php/omet/article/view/6540 |
| _version_ |
1716852773072404480 |